23 November 2016 - CADTH recommends use of levofloxacin inhalation solution.

The CADTH Canadian Drug Expert Committee has recommended that levofloxacin inhalation solution be reimbursed for the management of cystic fibrosis in patients 18 years or older with chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infections, if the following conditions are met:

• The drug is prescribed by a clinician with experience in the diagnosis and treatment of CF.
  
• The drug is not used in combination with another inhaled antibiotic(s) to treat pulmonary P. aeruginosa infections, either concurrently or for antibiotic cycling during off-treatment periods.
  
• Price of the drug does not exceed that of the least expensive available indicated inhaled antimicrobial alternative.
  

Read CADTH outcome for Quinsair